138In Schedule 12A (pharmaceutical remuneration), in paragraph 2—
(a)in the heading for “clinical commissioning groups” substitute “integrated care boards”;
(b)in sub-paragraph (3), for “clinical commissioning group” substitute “integrated care board”;
(c)in sub-paragraph (4), for “clinical commissioning groups” substitute “integrated care boards”;
(d)in sub-paragraph (5), for “clinical commissioning group” substitute “integrated care board”;
(e)in sub-paragraph (6)—
(i)for “a clinical commissioning group” substitute “an integrated care board”;
(ii)in paragraphs (a) and (b), for “the group”, in both places it occurs, substitute “the board”;
(f)in sub-paragraph (8), for “a clinical commissioning group” substitute “an integrated care board”;
(g)for sub-paragraph (9) substitute—
“(9)For the purposes of sections 223GC and 223M(1)(b) and paragraph 22 of Schedule 1B, any amount of which an integrated care board is notified under sub-paragraph (6) is to be treated as expenditure of the group which is attributable to the performance by it of its functions in the year in question.”